N-(4-chlorophenyl)-3,4-dimethoxyaniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-chlorophenyl)-3,4-dimethoxyaniline
• 化学式: C₁₄H₁₄ClNO₂
• 分子量: 263.724
• InChiKey: OLGSBTGUXAKEDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-chlorophenyl)-3,4-dimethoxyaniline 在 正丁基锂 、 palladium [2'-(amino-κN)[1,1'-biphenyl]-2-yl-κC][[5-(diphenylphosphino)-9,9-dimethyl-9H-xanthen-4-yl]diphenylphosphine-κP](methanesulfonato-κO) 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 24.0h， 生成 10-(4-Chlorophenyl)-2,2',3,3'-tetramethoxyspiro[acridine-9,9'-fluorene]
  参考文献：
  名称：

  Spirocentric Compounds and Polymers Thereof

  摘要：

  本发明涉及新型功能化螺环化合物及其聚合物，可产生超刚性交联膜。

  公开号：

  US20190276454A1
• 作为产物：
  描述：

  3,4-二甲氧基苯胺 、 alkaline earth salt of/the/ methylsulfuric acid 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 为溶剂， 以75%的产率得到N-(4-chlorophenyl)-3,4-dimethoxyaniline
  参考文献：
  名称：

  Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents

  摘要：

  On the basis of deguelin, a series of the B, C-ring truncated surrogates with N-substituted amide linkers were investigated as HSP90 inhibitors. The structure activity relationship of the template was studied by incorporating various substitutions on the nitrogen of the amide linker and examining their HIF-1 alpha inhibition. Among them, compound 57 showed potent HIF-1 alpha inhibition and cytotoxicity in triple-negative breast cancer lines in a dose-dependent manner. Compound 57 downregulated expression and phosphorylation of major client proteins of HSP90 including AKT, ERK and STAT3, indicating that its antitumor activity was derived from the inhibition of HSP90 function. The molecular modeling of 57 demonstrated that 57 bound well to the C-terminal ATP-binding pocket in the open conformation of the hHSP90 homodimer with hydrogen bonding and pi-cation interactions. Overall, compound 57 is a potential antitumor agent for triple-negative breast cancer as a HSP90 Cterminal inhibitor.

  DOI：

  10.1016/j.bmc.2019.02.040

文献信息

• Spirocentric compounds and polymers thereof
  申请人：Georgia Tech Research Corporation

  公开号：US10953369B2

  公开（公告）日：2021-03-23

  The present invention is directed to novel functionalized spirocentric compounds and polymers thereof that produce hyper-rigid cross-linked membranes.

  本发明涉及可产生超刚性交联膜的新型官能化螺环化合物及其聚合物。
• [EN] SPIROCENTRIC COMPOUNDS AND POLYMERS THEREOF<br/>[FR] COMPOSÉS SPIROCENTRIQUES ET POLYMÈRES DE CEUX-CI
  申请人：EXXONMOBIL RES & ENG CO

  公开号：WO2019173646A1

  公开（公告）日：2019-09-12

  The present invention is directed to novel functionalized spirocentric compounds and polymers thereof that produce hyper-rigid cross-linked membranes.
• Spirocentric Compounds and Polymers Thereof
  申请人：Georgia Tech Research Corporation

  公开号：US20190276454A1

  公开（公告）日：2019-09-12

  The present invention is directed to novel functionalized spirocentric compounds and polymers thereof that produce hyper-rigid cross-linked membranes.

  本发明涉及新型功能化螺环化合物及其聚合物，可产生超刚性交联膜。
• Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents
  作者：Ho Shin Kim、Van-Hai Hoang、Mannkyu Hong、Kyung Chul Kim、Jihyae Ann、Cong-Truong Nguyen、Ji Hae Seo、Hoon Choi、Jun Yong Kim、Kyu-Won Kim、Woong Sub Byun、Sangkook Lee、Seungbeom Lee、Young-Ger Suh、Jie Chen、Hyun-Ju Park、Tae-Min Cho、Ji Young Kim、Jae Hong Seo、Jeewoo Lee

  DOI：10.1016/j.bmc.2019.02.040

  日期：2019.4

  On the basis of deguelin, a series of the B, C-ring truncated surrogates with N-substituted amide linkers were investigated as HSP90 inhibitors. The structure activity relationship of the template was studied by incorporating various substitutions on the nitrogen of the amide linker and examining their HIF-1 alpha inhibition. Among them, compound 57 showed potent HIF-1 alpha inhibition and cytotoxicity in triple-negative breast cancer lines in a dose-dependent manner. Compound 57 downregulated expression and phosphorylation of major client proteins of HSP90 including AKT, ERK and STAT3, indicating that its antitumor activity was derived from the inhibition of HSP90 function. The molecular modeling of 57 demonstrated that 57 bound well to the C-terminal ATP-binding pocket in the open conformation of the hHSP90 homodimer with hydrogen bonding and pi-cation interactions. Overall, compound 57 is a potential antitumor agent for triple-negative breast cancer as a HSP90 Cterminal inhibitor.